Cyclacel jumps on seliciclib data

Shares of Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) continued to gain on Friday after the company reported preclinical data on Thursday for seliciclib in non-small cell lung cancer (NSCLC). In 52 cell lines of NSCLC origin, 12 of the 13 cell lines that had the highest sensitivity to seliciclib in vitro also had Ras-activating mutations, while no Ras-activating mutations were observed in the 15 cell lines that had the least sensitivity to seliciclib. The inhibitor of cyclin dependent kinases 2E, 2A, 7 and 9 is in Phase II testing to treat NSCLC and nasopharyngeal cancer. Data were published in Clinical Cancer Research. ...